Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Thomas Schinecker, Amelia Warner, Bartu Ahiska, More

Thomas Schinecker, Barbara Schädler, Michael Heuer, Stephan Feldhaus, Peter Voser

Thomas Schinecker has been appointed as CEO of Roche Diagnostics and a member of the firm's corporate executive committee, effective August 1. He will succeed Michael Heuer, who is retiring at the end of July. Schinecker is currently head of Centralized and Point of Care Solutions at Roche Diagnostics. Previously, he was general manager for Roche Diagnostics Germany, and before that, he held various management positions in marketing and sales as well as product development at Roche Diagnostics. He holds a PhD in molecular biology from New York University.

Barbara Schädler will become head of group communications and a member of Roche's enlarged Corporate Executive Committee, effective October 1. She will succeed Stephan Feldhaus, who will leave Roche at the end of September. Schädler is currently head of communications and public affairs at E.ON. Previously, she held communications manager positions at Lufthansa, SAP, and the German Federal Ministry of Finance. She holds a master's degree in economics from the University of Mainz.

Peter Voser will step down from the board of directors of Roche at the end of June due to his additional role as interim CEO of ABB.


Amelia Warner

Predictive Oncology has appointed Amelia Warner as the interim chief operating officer of its Helomics subsidiary. Prior to joining Helomics, Warner founded Global Specimens Solutions in 2013. Before GSS, Warner served as CEO for Gentris. She has also served as head of clinical pharmacogenomics and clinical specimen management for Merck. In addition, she has served as chair of the Industry Pharmacogenomics Working Group.


Bartu Ahiska

Oxford Biodynamics has appointed Bartu Ahiska as senior vice president (commercial) to spearhead commercialization of the company's EpiSwitch technology platform. Ahisku joins OBD from the Knight Cancer Early Detection Advanced Research Center at Oregon Health & Science University in Portland, where he has been the manager of innovation, IP, and and commercialization since 2016. He was a cofounder and remains a non-executive director of Trogenex in San Diego, and was COO and CEO of cloud-computing company Approxy before its acquisition by Numecent.


For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.